# EDGAR Filing Document

**Accession Number:** 0001625297
**File Stem:** 0001625297-25-000078
**Filing Date:** 2025-12
**Character Count:** 6771
**Document Hash:** 0b132fb5bab0df8272d49d22136b6be1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001625297-25-000078.hdr.sgml**: 20251222

**ACCESSION NUMBER**: 0001625297-25-000078

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251222

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251222

**DATE AS OF CHANGE**: 20251222

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INDIVIOR PLC
- **CENTRAL INDEX KEY:** 0001625297
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37835
- **FILM NUMBER:** 251589417

**BUSINESS ADDRESS:**
- **STREET 1:** 234 BATH ROAD
- **CITY:** SLOUGH, BERKSHIRE
- **STATE:** X0
- **ZIP:** SL1 4EE
- **BUSINESS PHONE:** 804-379-1090

**MAIL ADDRESS:**
- **STREET 1:** 234 BATH ROAD
- **CITY:** SLOUGH, BERKSHIRE
- **STATE:** X0
- **ZIP:** SL1 4EE

?xml version='1.0' encoding='ASCII'? indv-20251222

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 22, 2025

**INDIVIOR PLC**

(Exact name of registrant as specified in its charter)

England and Wales 001-37835 98-1204773 <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

10710 Midlothian Turnpike, Suite 125North Chesterfield, VA 23235 <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 804-379-1040

not applicable <br> (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Ordinary shares, $0.50 nominal value per share | INDV | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

**Item 7.01 Regulation FD Disclosure.**

On December 22, 2025, Indivior PLC (the "Company" or "Indivior") issued a press release announcing the inclusion of its ordinary shares in the S&P SmallCap 600® equity index. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein.

**Item 9.01 Exhibits**

*(d) Exhibits.*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [P](ex991sp600.htm)[ress release](ex991sp600.htm) dated December 22, 2025. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | **Indivior PLC** |
| &nbsp;&nbsp;Date: December 22, 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: | /s/ Ryan Preblick |
|  |  | Name: Ryan Preblick |
|  |  | Title: Chief Financial Officer |

---

## Exhibit 99.1

**<u>Exhibit 99.1</u>**

![image_0.jpg](image_0.jpg)

**<u>Indivior Announces Inclusion in the S&P SmallCap 600® Index</u>**

**Richmond, VA, December 22, 2025** – Indivior PLC (Nasdaq: INDV) ("**Indivior PLC**" or the "**Company**") today announced that it will be added to the S&P SmallCap 600® index, effective today.

"Indivior's inclusion in the S&P SmallCap 600 index marks an important milestone for Indivior that further aligns our capital markets presence with our sharpened U.S. business profile," said Joe Ciaffoni, Chief Executive Officer. "We are committed to growing SUBLOCADE®, our number one prescribed, first-in-class long-acting injectable treatment for moderate to severe opioid use disorder, as we leverage our new and simplified operating model."

The S&P SmallCap 600 Index is a stock market index established by Standard & Poor's that is designed to measure the performance of the small-cap segment of the market and is composed of 600 constituent companies in the U.S. equities market with market capitalizations between $1.2 billion and $8.0 billion. The index is designed to track companies that meet specific inclusion criteria to ensure that they are liquid and financially viable. For more information on the S&P SmallCap 600 and S&P Dow Jones Indices, please visit <u>www.spdji.com</u>.

**<u>About Indivior</u>**

Indivior Pharmaceuticals works to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a human crisis to a recognized and treated chronic disease. Building on its portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Visit <u>www.indivior.com</u> to learn more. Connect with Indivior on LinkedIn by visiting <u>www.linkedin.com/company/Indivior</u>.

**<u>For Further Information</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Investors** | Jason Thompson | VP, Investor Relations<br>Indivior PLC  | +1 804 402 7123<br>jason.thompson@indivior.com |
| **Media** | Cassie France-Kelly | VP, Communications Indivior PLC | +1 804 594 0836<br><u>Indiviormediacontacts@indivior.com</u> |

---

-ends-

<br>